AgomAb Therapeutics NV - ADR opened lower at $6.90, compared with its previous close of $6.99. In the last trading session, the stock traded between $6.34 and $6.98. It showed a downward intraday trend.
An investment of $100 made 1 year ago in AgomAb Therapeutics NV - ADR is now worth
$ 43.17
Resulting in a loss of
$ 56.83 (56.83%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.67 (-9.51%)
Day High
$6.98
Day Low
$6.34
Day Open
$6.90
Prev Close
$6.99
Volume
14,99,936
1W Return
-7.66%
1M Return
-30.29%
3M Return
-57.71%
6M Return
-48.07%
1Y Return
-56.83%
Market Cap ($ Mn)
-
PE Ratio
-
PB Ratio
2.27
PEG Ratio
-
ROE
-43.53%
ROCE
-39.37%
EPS (TTM)
-
1 Week
-7.66%
1 Month
-30.29%
3 Months
-57.71%
6 Months
-48.07%
9 Months
-60.47%
Agomab doses first patient in NOV-ERA Phase 2b study for FSCD
Agomab doses first patient in global Phase 2b NOV-ERA study for FSCD. NOV-ERA will enroll approximately 320 adults across three dose levels and placebo. New 400 mg BID arm added based on positive long-term safety data from Phase 2a OLE. Primary endpoint is endoscopic passability of ileal index stricture at Week 24.
1mo agoAgomab shares drop 17% despite positive long-term Crohn's trial data
Agomab Therapeutics shares fell 17.75% to $9.13 following the announcement. Phase 2a STENOVA trial showed a 3% annualized event rate for ontunisertib. Clinical remission achieved by 97% of evaluable patients at Week 48. Zero surgeries reported during the 60-week treatment period. Global Phase 2b NOV-ERA trial planned for approximately 320 patients.
1mo agoAgomab AGMB-447 shows positive Phase 1 IPF data, plans Phase 2
Agomab reports positive Phase 1 data for AGMB-447 in IPF patients. Drug showed favorable safety at 4.5 mg BID with >50% pSMAD3 reduction. Lung-restricted profile confirmed with low systemic exposure. Phase 2 INSPIRIA study CTA submitted; initiation planned for late 2026.
1mo agoAgomab Therapeutics appoints Marino Garcia, Dr. Naimish Patel to board
Shareholders appointed Marino Garcia and Dr. Naimish Patel as non-executive directors. Resolutions approved at Special General Meeting held in Antwerp on September 11, 2026. Pre-IPO warrants adjusted to align with February 2026 IPO share split. New directors bring strategic and clinical development expertise.
2mo agoPiper Sandler initiates AgomAb Therapeutics coverage with $60 target
Piper Sandler initiates coverage on AgomAb Therapeutics (NASDAQ: AGMB). Analyst Yasmeen Rahimi assigns an Overweight rating to the stock. Price target set at $60 per share. Coverage marks the firm's first published view on the company.
2mo agoAgomab Therapeutics nominates Garcia, Patel to board
Agomab Therapeutics NV proposes Marino Garcia and Dr. Naimish Patel for non-executive board seats, citing their expertise in biotech growth and clinical development. Shareholders will vote on these appointments and pre-IPO warrant adjustments at meetings on September 11, 2026.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 1 year ago in AgomAb Therapeutics NV - ADR is now worth
$ 43.17
Resulting in a loss of
$ 56.83 (56.83%)
Note: Past profits do not guarantee future returns.
